Table 3 Analyses of the impact of co-administered drugs on hepatotoxicity following MTX therapy using the FAERS database.

From: Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein

Co-administered drug

MTX-induced hepatotoxicity (%)

ROR

(95% CI)

p-value

Without drug

With drug

FBX

8,752/98,445 (9)

41/142 (29)

4.16 (2.89–5.98)

<0.001

Allopurinol

8,708/97,592 (9)

85/995 (9)

0.95 (0.76–1.19)

0.717

Lansoprazole

8,654/96,991 (9)

139/1,596 (9)

0.97 (0.82–1.16)

0.801

Rabeprazole

8,749/98,033 (9)

44/554 (8)

0.88 (0.65–1.20)

0.463

  1. MTX-induced hepatotoxicity presented as cases/(cases + non-cases) (%).
  2. Chi-square test was performed.
  3. CI: confidence interval, FAERS: FDA adverse event reporting system, FBX: febuxostat, MTX: methotrexate, ROR: reporting odds ratio.
Back to article page